Larry Todd Edwards net worth and biography

Larry Edwards Biography and Net Worth

Mr Edwards joined Arcutis in September 2023 as chief commercial officer and is responsible for overseeing and managing all commercial operations for Arcutis. Mr Edwards brings over 25 years of sales, market access, marketing, and general management experience. Prior to joining Arcutis, he spent almost three years at Incyte as group vice president and business unit head of immunology where he led the successful launch and commercialization of their topical JAK inhibitor for atopic dermatitis. Prior to that Mr Edwards was at UCB for nearly eight years as the head of US immunology and later head of global immunology operations and strategy, where he was instrumental in leading commercialization of their dermatology, rheumatology, and gastroenterology portfolios. Prior to that, he held senior roles at AbbVie and TAP Pharmaceuticals. Mr Edwards holds a BS from East Tennessee State University and an MBA from Embry-Riddle Aeronautical University. He is also a decorated veteran of the US Army.

What is Larry Todd Edwards' net worth?: The estimated net worth of Larry Todd Edwards is at least $2.01 million as of November 30th, 2024. Edwards owns 137,728 shares of Arcutis Biotherapeutics stock worth more than $2,013,583 as of March 15th. This net worth evaluation does not reflect any other assets that Edwards may own. Learn More about Larry Todd Edwards' net worth.
How do I contact Larry Todd Edwards?: The corporate mailing address for Edwards and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at ir@arcutis.com. Learn More on Larry Todd Edwards' contact information.
Has Larry Todd Edwards been buying or selling shares of Arcutis Biotherapeutics?: Larry Todd Edwards has not been actively trading shares of Arcutis Biotherapeutics over the course of the past ninety days. Most recently, on Saturday, November 30th, Larry Todd Edwards bought 1,093 shares of Arcutis Biotherapeutics stock. The stock was acquired at an average cost of $7.11 per share, with a total value of $7,771.23. Following the completion of the transaction, the insider now directly owns 137,728 shares of the company's stock, valued at $979,246.08. Learn More on Larry Todd Edwards' trading history.
Who are Arcutis Biotherapeutics' active insiders?: Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Terrie Curran (Director), Larry Edwards (Insider), Masaru Matsuda (General Counsel), David Topper (CFO), Patricia Turney (SVP), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?: During the last year, Arcutis Biotherapeutics insiders bought shares 1 times. They purchased a total of 1,093 shares worth more than $7,771.23. During the last year, insiders at the sold shares 25 times. They sold a total of 204,162 shares worth more than $2,214,551.74. The most recent insider tranaction occured on March, 3rd when insider Patrick Burnett sold 2,819 shares worth more than $36,731.57. Insiders at Arcutis Biotherapeutics own 9.5% of the company. Learn More about insider trades at Arcutis Biotherapeutics.
Information on this page was last updated on 3/3/2025.

Larry Todd Edwards Insider Trading History at Arcutis Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/30/2024	Buy	1,093	$7.11	$7,771.23	137,728
10/2/2024	Sell	3,725	$10.01	$37,287.25	136,635
5/17/2024	Sell	7,640	$8.98	$68,607.20	140,360

Larry Todd Edwards Buying and Selling Activity at Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Today's Range

Now: $14.62

$14.51

$15.38

50 Day Range

MA: $13.52

$11.40

$15.76

2 Week Range

Now: $14.62

$6.99

$16.20

Volume

1,689,885 shs

Average Volume

2,433,515 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48